You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Article metrics

Article menu

Download PDFPDF

XML
Research Article
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

 

Online download statistics by month:

Online download statistics by month: December 2019 to June 2022

AbstractFullPdf
Dec 2019771
Jan 202021210
Feb 2020515114
Mar 2020707125
Apr 2020484827
May 2020767635
Jun 2020464614
Jul 2020666625
Aug 2020474730
Sep 2020575719
Oct 2020949431
Nov 2020676719
Dec 2020797929
Jan 2021939346
Feb 2021737329
Mar 2021848429
Apr 2021898965
May 2021787850
Jun 2021595930
Jul 2021545431
Aug 2021717153
Sep 2021636345
Oct 2021676757
Nov 2021727251
Dec 2021616236
Jan 2022647339
Feb 2022667737
Mar 2022656635
Apr 2022707729
May 2022686837
Jun 2022555530
Total19812011998